BioNTech AG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:BioNTech AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10663
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioNTech AG (BioNTech) is a biopharmaceutical company that develops biomarker based diagnostics. The company’s products include RNXtract and mammatyper, and cell and gene therapies. It pipeline products include BioNTech mRNA pharmaceuticals, BioNTech cell and gene, BioNTech small molecules and BioNTech protein therapeutics. BioNTech’s protein therapy platforms include bispecific antibodies, microbodies and virus like particles developed for cancer immunotherapy. The company offers diagnostic products and drug discovery services for other therapeutic areas such as infectious diseases, allergies, and autoimmune disorders. It operates a research and development facility in Germany. BioNTech is headquartered in Mainz, Germany.

BioNTech AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioNTech AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioNTech AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioNTech AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioNTech AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BioNTech AG, Medical Devices Deals, 2012 to YTD 2018 10
BioNTech AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
BioNTech AG, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
BioNTech Raises USD270 Million in Series A Venture Financing 13
Partnerships 14
BioNTech and Genevant Sciences Enter into Co-Development Agreement 14
BioNTech and University of Pennsylvania Enter into Research Collaboration 15
BioNTech Enters into R&D Agreement with Pfizer 16
Scancell Enters into Research Agreement with BioNTech 17
MAB Discovery Enters into Agreement with BioNTech 18
BioNTech Enters into Agreement with Genentech 19
PCI Biotech Enters into Research Agreement with BioNTech 20
Genmab Enters into Co-Development Agreement with BioNTech 21
Eli Lilly Enters into Research Agreement with BioNTech 22
Plexera Biotech Enters into Distribution Agreement with JPT Peptide 23
MAB Discovery Enters into Research Agreement with BioNTech for Monoclonal Antibody Products 24
4SC Discovery Enters Into Research Agreement With Biontech 25
JPT Peptide Technologies Enters Into Agreement With Instituts Fur Medizinische Immunologie 26
Tecan Enters Into Co-Promotion Agreement With JPT Peptide Technologies For Array Products 27
4SC Enters Into Co-Development Agreement With Crelux And Ribological 28
JPT Peptide Technologies, IUCT And LEITAT Enters Into Co-Development Agreement 29
Licensing Agreements 30
BioNTech Enters into Licensing Agreement with Cellscript 30
Sanofi Enters into Licensing Agreement with BioNTech 31
4SC Discovery Enters Into Licensing Agreement With BioNTech For TLR Agonists 32
Acquisition 33
BioNTech Small Molecules Acquires 4SC Discovery from 4SC 33
BioNTech AG – Key Competitors 34
BioNTech AG – Key Employees 35
BioNTech AG – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Corporate Communications 37
May 29, 2018: BioNTech Names Dr. Ozlem Tureci As Chief Medical Officer 37
Product News 38
03/07/2017: BioNTech to Present Interim Phase I/II Data for Investigational mRNA Vaccine in Melanoma Patients at AACR Annual Meeting 2017 38
Other Significant Developments 39
Oct 04, 2017: BioNTech Manufacturing Subsidiary, EUFETS, Becomes BioNTech Innovative Manufacturing Services 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
BioNTech AG, Pharmaceuticals & Healthcare, Key Facts 2
BioNTech AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioNTech AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioNTech AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioNTech AG, Deals By Therapy Area, 2012 to YTD 2018 9
BioNTech AG, Medical Devices Deals, 2012 to YTD 2018 10
BioNTech AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
BioNTech Raises USD270 Million in Series A Venture Financing 13
BioNTech and Genevant Sciences Enter into Co-Development Agreement 14
BioNTech and University of Pennsylvania Enter into Research Collaboration 15
BioNTech Enters into R&D Agreement with Pfizer 16
Scancell Enters into Research Agreement with BioNTech 17
MAB Discovery Enters into Agreement with BioNTech 18
BioNTech Enters into Agreement with Genentech 19
PCI Biotech Enters into Research Agreement with BioNTech 20
Genmab Enters into Co-Development Agreement with BioNTech 21
Eli Lilly Enters into Research Agreement with BioNTech 22
Plexera Biotech Enters into Distribution Agreement with JPT Peptide 23
MAB Discovery Enters into Research Agreement with BioNTech for Monoclonal Antibody Products 24
4SC Discovery Enters Into Research Agreement With Biontech 25
JPT Peptide Technologies Enters Into Agreement With Instituts Fur Medizinische Immunologie 26
Tecan Enters Into Co-Promotion Agreement With JPT Peptide Technologies For Array Products 27
4SC Enters Into Co-Development Agreement With Crelux And Ribological 28
JPT Peptide Technologies, IUCT And LEITAT Enters Into Co-Development Agreement 29
BioNTech Enters into Licensing Agreement with Cellscript 30
Sanofi Enters into Licensing Agreement with BioNTech 31
4SC Discovery Enters Into Licensing Agreement With BioNTech For TLR Agonists 32
BioNTech Small Molecules Acquires 4SC Discovery from 4SC 33
BioNTech AG, Key Competitors 34
BioNTech AG, Key Employees 35
BioNTech AG, Subsidiaries 36

List of Figures
BioNTech AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioNTech AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioNTech AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioNTech AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioNTech AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioNTech AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
BioNTech AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioNTech AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BioNTech AG, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[BioNTech AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Molex LLC:企業のM&A・事業提携・投資動向
    Molex LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Molex LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Golden Gate Capital:企業の戦略的SWOT分析
    Golden Gate Capital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Vectren Corporation (VVC)-エネルギー分野:企業M&A・提携分析
    Summary Vectren Corporation (Vectren) is an energy holding company, which carries out the distribution and transmission of natural gas and electricity. Under its wholly owned subsidiary, Vectren Utility Holdings, Inc., the company operates three utilities; Vectren Energy Delivery of Indiana - North …
  • Hub Group Inc (HUBG):企業の財務・戦略的SWOT分析
    Hub Group Inc (HUBG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • TOLMAR Inc-製薬・医療分野:企業M&A・提携分析
    Summary TOLMAR Inc (TOLMAR), a subsidiary of Tolmar Holding Inc is a developer, manufacturer and distributor of pharmaceutical products. The company provides generic dermatology products such as creams, gels, ointments and solutions. It also provides levetiracetam oral solutions including antiepilep …
  • Chiesi Farmaceutici SpA:企業の戦略的SWOT分析
    Chiesi Farmaceutici SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Tenneco Inc (TEN):企業の財務・戦略的SWOT分析
    Tenneco Inc (TEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bloomberg L.P.:企業の戦略・SWOT・財務分析
    Bloomberg L.P. - Strategy, SWOT and Corporate Finance Report Summary Bloomberg L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Paratek Pharmaceuticals Inc (PRTK):企業の財務・戦略的SWOT分析
    Paratek Pharmaceuticals Inc (PRTK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Cytokinetics Inc (CYTK):製薬・医療:M&Aディール及び事業提携情報
    Summary Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases associated with reduced muscle performance. The company’s pipeline encompasses omecamtiv mecarbil, a novel cardiac myosin a …
  • Laboratoires Pierre Fabre SA-製薬・医療分野:企業M&A・提携分析
    Summary Laboratoires Pierre Fabre SA (Pierre Fabre), a subsidiary of Pierre Fabre Foundation develops products and solutions ranging from health to beauty. Its product portfolio comprises wide range of complementary products, from prescribed drugs to dermo-cosmetics, including over-the-counter drugs …
  • Shanghai Kehua Bio-engineering Co Ltd (002022):製薬・医療:M&Aディール及び事業提携情報
    Summary Shanghai Kehua Bio-engineering Co Ltd (KHB) is a medical device company that develops, manufactures and markets in vitro diagnostic devices and related products. The company’s major product portfolio includes enzyme immunoassay kits, clinical chemistry reagents, PCR kits, rapid test kits, ch …
  • The Interpublic Group of Companies, Inc.:企業の戦略・SWOT・財務分析
    The Interpublic Group of Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Interpublic Group of Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Lepu Medical Technology (Beijing) Co Ltd (300003):製薬・医療:M&Aディール及び事業提携情報
    Summary Lepu Medical Technology (Beijing) Co Ltd (Lepu Medical) is a medical technology company that offers medical equipments, pharmaceutical products and healthcare services. The company’s products include cardiovascular interventional products, surgical cardiology products, peripheral interventio …
  • Intermountain Healthcare Inc-製薬・医療分野:企業M&A・提携分析
    Summary Intermountain Healthcare Inc (Intermountain Healthcare) is a non-profit health care system. It provides health care services to Utah and Southeastern Idaho residents. It offers a wide range of clinical programs covering cardiovascular, intensive medicine, primary care, pediatric specialties, …
  • Nan Ya Plastics Corporation:企業の戦略・SWOT・財務情報
    Nan Ya Plastics Corporation - Strategy, SWOT and Corporate Finance Report Summary Nan Ya Plastics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Melbana Energy Ltd (MAY):石油・ガス:M&Aディール及び事業提携情報
    Summary Melbana Energy Ltd (Melbana), formerly MEO Australia Ltd, is an oil and gas exploration and production company. The company carries out acquisition, exploration and development of oil and gas properties. Its projects include Cuba – Block 9 PSC, Taranaki Basin, Petrel Sub-Basin Exploration, T …
  • CellaVision AB (CEVI):医療機器:M&Aディール及び事業提携情報
    Summary CellaVision AB (CellaVision) is a medical technology company that provides digital solutions for medical microscopy in hematology. The company helps hematology laboratories improve and transform the analysis of blood and other body fluids. It has expertise in digital image analysis, automate …
  • Medigus Ltd (MDGS)-医療機器分野:企業M&A・提携分析
    Summary Medigus Ltd (Medigus) is a medical equipment provider that offers endoscopic procedures and devices. The company’s muse system enables endoscopists to treat gastroesophageal reflux disease by performing fundoplication procedures through the mouth. It offers various rigid, semi-flexible and f …
  • Petoro AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Petoro AS (Petoro) is an oil and gas asset management company. The company manages Norwegian state’s direct financial interests (SDFI) in Norwegian Continental Shelf (NCS) oil and gas assets. It has the responsibility for and to attend to the commercial aspects related to the state's direct …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆